Literature DB >> 25801315

Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders.

Claire M A LeBlanc1, Jinhui Ma2, Monica Taljaard2, Johannes Roth3, Rosie Scuccimarri1, Paivi Miettunen4, Bianca Lang5, Adam M Huber5, Kristin Houghton6, Jacob L Jaremko7, Josephine Ho4, Nazih Shenouda8, Mary Ann Matzinger8, Brian Lentle9, Robert Stein10, Anne Marie Sbrocchi1, Kiem Oen11, Celia Rodd11, Roman Jurencak3, Elizabeth A Cummings5, Robert Couch12, David A Cabral6, Stephanie Atkinson13, Nathalie Alos14, Frank Rauch1, Kerry Siminoski15, Leanne M Ward3.   

Abstract

Vertebral fractures are an important yet underrecognized manifestation of osteoporosis in children with chronic, glucocorticoid-treated illnesses. Our goal was to determine the incidence and clinical predictors of vertebral fractures in the 3 years following glucocorticoid initiation among pediatric patients with rheumatic disorders. Incident vertebral fractures were evaluated according to the Genant semiquantitative method on lateral radiographs at baseline and then annually in the 3 years following glucocorticoid initiation. Extended Cox models were used to assess the association between vertebral fractures and clinical risk predictors. A total of 134 children with rheumatic disorders were enrolled in the study (mean ± standard deviation (SD) age 9.9 ± 4.4 years; 65% girls). The unadjusted vertebral fracture incidence rate was 4.4 per 100 person-years, with a 3-year incidence proportion of 12.4%. The highest annual incidence occurred in the first year (6.0%; 95% confidence interval (CI) 2.9% to 11.7%). Almost one-half of the patients with fractures were asymptomatic. Every 0.5 mg/kg increase in average daily glucocorticoid (prednisone equivalents) dose was associated with a twofold increased fracture risk (hazard ratio (HR) 2.0; 95% CI 1.1 to 3.5). Other predictors of increased vertebral fracture risk included: (1) increases in disease severity scores between baseline and 12 months; (2) increases in body mass index Z-scores in the first 6 months of each 12-month period preceding the annual fracture assessment; and (3) decreases in lumbar spine bone mineral density Z-scores in the first 6 months of glucocorticoid therapy. As such, we observed that a clinically significant number of children with rheumatic disorders developed incident vertebral fractures in the 3 years following glucocorticoid initiation. Almost one-half of the children were asymptomatic and thereby would have been undiagnosed in the absence of radiographic monitoring. In addition, discrete clinical predictors of incident vertebral fractures were evident early in the course of glucocorticoid therapy.
© 2015 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ADOLESCENTS; BONE DENSITY; CHILDREN; GLUCOCORTICOIDS; RHEUMATIC DISORDERS; VERTEBRAL FRACTURES

Mesh:

Substances:

Year:  2015        PMID: 25801315      PMCID: PMC4556451          DOI: 10.1002/jbmr.2511

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  34 in total

1.  Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions.

Authors:  Nick Bishop; Paul Arundel; Emma Clark; Paul Dimitri; Joshua Farr; Graeme Jones; Outi Makitie; Craig F Munns; Nick Shaw
Journal:  J Clin Densitom       Date:  2014-03-14       Impact factor: 2.617

Review 2.  Ways of measuring rates of recurrent events.

Authors:  R J Glynn; J E Buring
Journal:  BMJ       Date:  1996-02-10

3.  Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy.

Authors:  S Varonos; B M Ansell; J Reeve
Journal:  Calcif Tissue Int       Date:  1987-08       Impact factor: 4.333

4.  Inter-observer agreement of the physician's global assessment of disease activity in children with juvenile idiopathic arthritis.

Authors:  A Falcone; R Cassone; E Rossi; A Pistorio; A Martini; A Ravelli
Journal:  Clin Exp Rheumatol       Date:  2005 Jan-Feb       Impact factor: 4.473

5.  Radiographic vertebral morphology: a diagnostic tool in pediatric osteoporosis.

Authors:  Outi Mäkitie; Andrea S Doria; Flavia Henriques; William G Cole; Sandrine Compeyrot; Earl Silverman; Ronald Laxer; Alan Daneman; Etienne B Sochett
Journal:  J Pediatr       Date:  2005-03       Impact factor: 4.406

6.  Vertebral fracture assessment using a semiquantitative technique.

Authors:  H K Genant; C Y Wu; C van Kuijk; M C Nevitt
Journal:  J Bone Miner Res       Date:  1993-09       Impact factor: 6.741

7.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  L G Rider; B M Feldman; M D Perez; R M Rennebohm; C B Lindsley; L S Zemel; C A Wallace; S H Ballinger; S L Bowyer; A M Reed; M H Passo; I M Katona; F W Miller; P A Lachenbruch
Journal:  Arthritis Rheum       Date:  1997-11

8.  Associations of birth weight and length, childhood size, and smoking with bone fractures during growth: evidence from a birth cohort study.

Authors:  Ianthe E Jones; Sheila M Williams; Ailsa Goulding
Journal:  Am J Epidemiol       Date:  2004-02-15       Impact factor: 4.897

9.  The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus.

Authors:  S D Marks; C Pilkington; P Woo; M J Dillon
Journal:  Rheumatology (Oxford)       Date:  2004-06-29       Impact factor: 7.580

10.  Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Authors:  K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  32 in total

Review 1.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

Review 2.  The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position.

Authors:  David R Weber; Alison Boyce; Catherine Gordon; Wolfgang Högler; Heidi H Kecskemethy; Madhusmita Misra; Diana Swolin-Eide; Peter Tebben; Leanne M Ward; Halley Wasserman; Christopher Shuhart; Babette S Zemel
Journal:  J Clin Densitom       Date:  2019-07-10       Impact factor: 2.617

Review 3.  [Fractures and bone mineral density in childhood].

Authors:  Christine Hofmann; Herrmann Girschick; Constantin Lapa; Oliver Semler; Franz Jakob
Journal:  Z Rheumatol       Date:  2019-09       Impact factor: 1.372

Review 4.  Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.

Authors:  Monica Grover; Laura K Bachrach
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 5.  Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

Authors:  Edoardo Marrani; Teresa Giani; Gabriele Simonini; Rolando Cimaz
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

6.  Use of dual energy X-ray absorptiometry in pediatric patients.

Authors:  Halley Wasserman; Jennifer M O'Donnell; Catherine M Gordon
Journal:  Bone       Date:  2016-12-15       Impact factor: 4.398

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

Review 8.  Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; David R Weber
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

Review 9.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

10.  Variation in Preventive Care in Children Receiving Chronic Glucocorticoid Therapy.

Authors:  Matthew L Basiaga; Evanette K Burrows; Michelle R Denburg; Kevin E Meyers; Andrew B Grossman; Petar Mamula; Robert W Grundmeier; Jon M Burnham
Journal:  J Pediatr       Date:  2016-09-09       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.